European Lithium reports strong rare earth results from Greenland, while Moderna launches its first mRNA cancer trial.

European Lithium Ltd reported strong assay results from its Tanbreez rare earths project in Greenland, with historic Hill deposit samples averaging 0.58% total rare earth oxides and 24.9% heavy rare earths, exceeding expectations. The company advanced its strategic focus by selling shares in Critical Metals Corp, generating capital, and continued de-risking its European lithium assets. Meanwhile, Moderna initiated a Phase 1/2 trial for mRNA-2808, its first cancer immunotherapy using mRNA technology, targeting relapsed multiple myeloma. Imugene’s allogeneic CAR-T therapy azer-cel received an oral presentation slot at the ASH 2025 meeting, showing early promise in treating relapsed large B-cell lymphoma. In healthcare, Genea Pty Ltd faces a representative complaint over a data breach exposing IVF patient information, raising privacy concerns. In financial markets, the U.S. stock market ended mixed, with tech stocks leading gains amid strong AI-related momentum.